Beijing Hotgen Biotech Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2021
August 25, 2021 at 11:16 am
Share
Beijing Hotgen Biotech Co., Ltd. announced earnings results for the half year ended June 30, 2021. For the half year, the company announced sales was CNY 3,599.723 million compared to CNY 89.900 million a year ago. Operating income was CNY 1,727.424 million compared to CNY 2.155 million a year ago. Net income was CNY 1,452.618 million compared to CNY 1.953 million a year ago. Basic earnings per share from continuing operations was CNY 23.36 compared to CNY 0.03 a year ago.
Beijing Hotgen Biotech Co Ltd is a China-based company mainly engaged in the research and development, production and sales of in vitro diagnostic reagents and instruments. The Company's products mainly include in vitro diagnostic reagents, in vitro diagnostic instruments and biological raw materials. Its products are mainly used in clinical fields such as liver cancer, hepatitis, cardiovascular and cerebrovascular diseases, and inflammatory infections, as well as in public safety and other fields such as biosafety, food safety, and disease control and emergency response. The Company primarily conducts its businesses in domestic and overseas markets.
BEIJING HOTGEN BIOTECH CO., LTD. 
